SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 134 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $6,389,250 | -5.5% | 440,031 | +36.2% | 0.55% | -16.5% |
Q2 2023 | $6,763,195 | -67.2% | 323,134 | -66.9% | 0.65% | -58.6% |
Q1 2023 | $20,606,890 | -17.0% | 975,705 | 0.0% | 1.58% | -1.9% |
Q4 2022 | $24,831,692 | -26.5% | 975,705 | -30.6% | 1.61% | -26.4% |
Q3 2022 | $33,773,000 | -34.1% | 1,405,428 | -47.2% | 2.19% | -14.9% |
Q2 2022 | $51,238,000 | +9.5% | 2,663,087 | -1.1% | 2.57% | +24.1% |
Q1 2022 | $46,792,000 | -29.9% | 2,692,303 | -11.7% | 2.07% | -11.9% |
Q4 2021 | $66,777,000 | +31.5% | 3,050,559 | +14.8% | 2.35% | +46.8% |
Q3 2021 | $50,778,000 | +14.0% | 2,657,159 | +2.5% | 1.60% | +26.5% |
Q2 2021 | $44,528,000 | -0.5% | 2,593,337 | +29.5% | 1.26% | -3.4% |
Q1 2021 | $44,774,000 | +11.9% | 2,002,410 | +11.3% | 1.31% | +5.6% |
Q4 2020 | $39,998,000 | +102.4% | 1,798,453 | +34.3% | 1.24% | +105.1% |
Q3 2020 | $19,759,000 | – | 1,338,691 | – | 0.60% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |